Clinical Trial Results:
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease
Summary
|
|
EudraCT number |
2018-004346-42 |
Trial protocol |
GB DE FR ES BG AT CZ HU BE IT SK RO |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Oct 2024
|
First version publication date |
27 Oct 2024
|
Other versions |
|
Summary report(s) |
d5271c00001-CSR study-synopsis redacted- 8th AUG_Redacted |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.